Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-06-14 Report Publication Anno…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia rapporterar fortsatta framsteg i pågående klinisk fas I-studie med CAN10
Report Publication Announcement Classification · 98% confidence The document is a press release from Cantargia AB announcing progress in its clinical Phase I study for the CAN10 antibody. It details safety results, receptor binding confirmation, and the timeline for the next dosing groups and the start of the multiple-dosing study in psoriasis patients. The text explicitly states that this information is being made public under the EU Market Abuse Regulation and provides contact information for further details. Crucially, at the end, under "Bifogade filer" (Attached files), it links to a PDF document titled with the same headline. Given the short length (under 5,000 characters) and the nature of announcing that a report/update is available (implied by the link), this fits the definition of a Report Publication Announcement (RPA), which announces the release of underlying information, rather than being the comprehensive report itself (like an ER or IR).
2024-06-14 Swedish
Cantargia reports further progress in ongoing phase 1 clinical trial with CAN10
Regulatory Filings Classification · 95% confidence The document is a press release titled "Cantargia reports further progress in ongoing phase 1 clinical trial with CAN10." It details updates on a clinical trial, safety data, receptor occupancy studies, and future timelines (Q3 dosing, biomarker results mid-2024). It concludes with boilerplate 'About Cantargia' information and an attachment link. This content structure—a news update on operational progress, often related to R&D or clinical milestones, released via a regulatory channel—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (10-K, IR, ER, etc.). Since it is an announcement of operational progress and not a formal financial report, and it doesn't fit other specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements.
2024-06-14 English
Cantargia strengthen management team with the appointment of Ton Berkien as Chief Business Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new Chief Business Officer (Ton Berkien) to the management team. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information'. The document is short and appears to be a regulatory news service (RNS) style announcement, but the core content is management change, making MANG the most specific fit over the general RNS category.
2024-06-11 English
Cantargia stärker ledningsgruppen genom rekryteringen av Ton Berkien som Chief Business Officer
Board/Management Information Classification · 100% confidence The document is a press release announcing the recruitment of a new Chief Business Officer (Ton Berkien) to the management team, effective October 1, 2024. This type of announcement, detailing changes in senior management personnel, directly corresponds to the definition of 'Board/Management Information'. The document is short and appears to be a formal announcement rather than a comprehensive report or a general regulatory filing fallback. Therefore, the appropriate code is MANG.
2024-06-11 Swedish
Cantargia presents new positive clinical data on nadunolimab counteracting chemotherapy induced neuropathy
Regulatory Filings Classification · 95% confidence The document is a press release announcing new clinical data regarding the drug nadunolimab and its effect on chemotherapy-induced neuropathy. It includes key results, quotes from the CEO, details about presentation at the ASCO Annual Meeting, and regulatory disclosure language ("This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation."). This format strongly suggests an immediate public disclosure of material, non-financial operational news, which typically falls under general Regulatory Filings (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period's results. Since it is focused on clinical trial data updates and presentation announcements rather than comprehensive financial statements (10-K, IR) or formal earnings highlights (ER), the most appropriate general category for such a material, non-standard announcement is Regulatory Filings (RNS). The document length (7311 chars) is substantial enough that it is the report itself, not just a brief announcement of a report (ruling out RPA).
2024-05-23 English
Cantargia presentar nya positiva kliniska data för nadunolimab och motverkande av cellgiftsinducerad neuropati
Regulatory Filings Classification · 90% confidence The document is a press release from Cantargia AB announcing new positive clinical data for their drug nadunolimab, specifically regarding its potential to counteract chemotherapy-induced neuropathy. It details study results (CANFOUR), mentions upcoming presentation at the ASCO Annual Meeting, and includes standard corporate boilerplate and contact information. The text concludes with a link to a PDF file titled similarly to the announcement itself, suggesting this text is the announcement *about* the data/presentation, not the full report or presentation itself. Since it is a formal announcement of clinical/research findings and is not a standard periodic financial report (10-K, IR, ER), nor a proxy statement (DEF 14A), nor a management discussion (MDA), it fits best as a general regulatory announcement or a specific type of investor communication. Given the content is a detailed update on clinical trial results and upcoming presentation, it is highly relevant to investors. However, it is not a standard Earnings Release (ER) or Interim Report (IR). It is a specific announcement of research progress. Since there is no specific code for 'Clinical Trial Update' or 'Research Announcement', and it is a formal, time-sensitive disclosure, it falls under the general category of regulatory/investor news. The presence of a link to a PDF attachment and the nature of the content (announcing data presentation) suggests it could be an RPA, but since it contains substantial narrative detail rather than just announcing the report's availability, it is more likely a specific type of investor communication. Given the options, and recognizing this is a formal disclosure of material information that isn't a standard financial filing, 'Regulatory Filings' (RNS) is the most appropriate fallback for a non-standard, material announcement, although 'Investor Presentation' (IP) might seem close if it were the presentation itself. Since it is an announcement *about* data being presented, RNS is the safest classification for a general regulatory disclosure that doesn't fit the other specific financial/governance codes.
2024-05-23 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.